Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a Small Molecule Antagonist of the Neuropeptide Y Y2 Receptor

Pascal Bonaventure, Diane Nepomuceno, Curt Mazur, Brian Lord, Dale A. Rudolph, Jill A. Jablonowski, Nicholas I. Carruthers and Timothy W. Lovenberg
Journal of Pharmacology and Experimental Therapeutics March 2004, 308 (3) 1130-1137; DOI: https://doi.org/10.1124/jpet.103.060459
Pascal Bonaventure
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diane Nepomuceno
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Curt Mazur
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Lord
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dale A. Rudolph
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jill A. Jablonowski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas I. Carruthers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy W. Lovenberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The in vitro pharmacological properties of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]-acrylamide (JNJ-5207787), a novel neuropeptide Y Y2 receptor (Y2) antagonist, were evaluated. JNJ-5207787 inhibited the binding of peptide YY (PYY) to human Y2 receptor in KAN-Ts cells (pIC50 = 7.00 ± 0.10) and to rat Y2 receptors in rat hippocampus (pIC50 = 7.10 ± 0.20). The compound was >100-fold selective versus human Y1,Y4, and Y5 receptors as evaluated by radioligand binding. In vitro receptor autoradiography data in rat brain tissue sections confirmed the selectivity of JNJ-5207787. [125I]PYY binding sites sensitive to JNJ-5207787 were found in rat brain regions known to express Y2 receptor (septum, hypothalamus, hippocampus, substantia nigra, and cerebellum), whereas insensitive binding sites were observed in regions known to express Y1 receptor (cortex and thalamus). JNJ-5207787 was demonstrated to be an antagonist via inhibition of PYY-stimulated guanosine 5′-O-(3-[35S]thio)triphosphate binding ([35S]GTPγS) in KAN-Ts cells (pIC50 corrected = 7.20 ± 0.12). This was confirmed auto-radiographically in rat brain sections where PYY-stimulated guanosine 5′-O-(3-[35S]thio)triphosphate binding was inhibited by JNJ-5207787 (10 μM) in hypothalamus, hippocampus, and substantia nigra. After intraperitoneal administration in rats (30 mg/kg), JNJ-5207787 penetrated into the brain (Cmax = 1351 ± 153 ng/ml at 30 min) and occupied Y2 receptor binding sites as revealed by ex vivo receptor autoradiography. Hence, JNJ-5207787 is a potent and selective pharmacological tool available to establish the potential role of central and peripheral Y2 receptors in vivo.

Footnotes

  • JNJ-5207787 will be made available upon request to Dr. T. Lovenberg, Johnson & Johnson Pharmaceutical Research and Development, LLC., 3210 Merryfield Row, San Diego CA 92121. E-mail: tlovenbe{at}prdus.jnj.com

  • DOI: 10.1124/jpet.103.060459.

  • ABBREVIATIONS: NPY, neuropeptide Y; PP, pancreatic polypeptide; PYY, peptide YY; CHO, Chinese hamster ovary; JNJ-5207787, N-(1-acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4-yl]-acrylamide); HEK-293, human embryonic kidney; PBS, phosphate-buffered saline; BIIE0246, (S)-N2-[[1-[2-[4-[(R,S)-5,11-dihydro-6(6h)-oxodibenz[b,e]azepin-11-yl]-1-piperazinyl]2-oxoethyl] acetyl]-N-[2-[1,2-di-hydro-3,5(4H)-dioxo-1,2-diphenyl-3H-1,2,4-triazol-4-yl]ethyl]-argininamide; BIBP-3226, R-N2-(diphenylacetyl)-N-(4-hydroxyphenyl)methyl argininamide; BSA, bovine serum albumin; GTPγS, guanosine-5′-O-(3-thio)-triphosphate; L-152804, 5,5-dimethyl-2-(2,3,4,9-tetrahydro-3,3-dimethyl-1oxo-1H-xanthene-9-yl)-1,3-cyclohexanedione; BNST, bed nucleus of the stria terminalis.

    • Received September 26, 2003.
    • Accepted November 5, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 308 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 308, Issue 3
1 Mar 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a Small Molecule Antagonist of the Neuropeptide Y Y2 Receptor
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a Small Molecule Antagonist of the Neuropeptide Y Y2 Receptor

Pascal Bonaventure, Diane Nepomuceno, Curt Mazur, Brian Lord, Dale A. Rudolph, Jill A. Jablonowski, Nicholas I. Carruthers and Timothy W. Lovenberg
Journal of Pharmacology and Experimental Therapeutics March 1, 2004, 308 (3) 1130-1137; DOI: https://doi.org/10.1124/jpet.103.060459

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleNEUROPHARMACOLOGY

Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a Small Molecule Antagonist of the Neuropeptide Y Y2 Receptor

Pascal Bonaventure, Diane Nepomuceno, Curt Mazur, Brian Lord, Dale A. Rudolph, Jill A. Jablonowski, Nicholas I. Carruthers and Timothy W. Lovenberg
Journal of Pharmacology and Experimental Therapeutics March 1, 2004, 308 (3) 1130-1137; DOI: https://doi.org/10.1124/jpet.103.060459
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CVN424, a novel GPR6 inverse agonist for Parkinson's disease
  • Methylone Brain Concentrations and Pharmacodynamic Effects
  • Oxysterols and Ethanol
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics